Sign up to save your podcasts
Or
Share Novo Nordisk pushes FDA to stop GLP1 compounding citing "complexity'
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Novo Nordisk pushes FDA to stop GLP1 compounding citing "complexity'
Today we discuss a major development: Novo Nordisk, the company behind WeGovy and Ozempic, is pushing the FDA to stop compounding pharmacies from manufacturing the compounded medications, citing the complexity of manufacture. Critics say it is just a ploy to secure profits.
View all episodes
By Bob Weigert & Julie AlmandineToday we discuss a major development: Novo Nordisk, the company behind WeGovy and Ozempic, is pushing the FDA to stop compounding pharmacies from manufacturing the compounded medications, citing the complexity of manufacture. Critics say it is just a ploy to secure profits.